Key result
A Newcastle Disease Virus-based vectored vaccine expressing poliovirus capsid proteins was designed to stimulate systemic and mucosal immune responses.
Supports NDV vector exploration for polio vaccines; leaves open clinical translation and efficacy.
A new, safe, and effective vaccine against poliovirus is urgently needed not only to complete the eradication of the virus but also to be used in the future to prevent possible virus reemergence in a postpolio world. Currently, new formulations of the oral vaccine, as well as improvements to the inactivated vaccine, are being explored. In this study, we designed a viral vector with mucosal tropism that expresses poliovirus capsid proteins. Thus, poliovirus VLPs are produced in vivo , in the cells of a vaccine recipient, and are presented to the immune system in the context of vector virus replication, stimulating the development of systemic and mucosal immune responses. Such an approach allows the development of an affordable and safe vaccine that does not rely on the full-length poliovirus genome at any stage.
No takes yet. Share an insight, caveat, or question.
Viktorova et al. (2018) studied Poliomyelitis. Newcastle Disease Virus-Based Vectored Vaccine was evaluated. A Newcastle Disease Virus-based vectored vaccine expressing poliovirus capsid proteins was designed to stimulate systemic and mucosal immune responses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: